Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi
The combined company is supported by $50 million in capital from Ligand and a group of outside investors. The team plans to launch the FDA-approved topical molluscum treatment Zelsuvmi this summer.
The combined company is supported by $50 million in capital from Ligand and a group of outside investors. The team plans to launch the FDA-approved topical molluscum treatment Zelsuvmi this summer.
